Literature DB >> 28069323

Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity.

Ryota Tanaka1, Naoko Okiyama2, Mari Okune1, Yosuke Ishitsuka1, Rei Watanabe1, Junichi Furuta1, Mikio Ohtsuka1, Atsushi Otsuka1, Hiroshi Maruyama1, Yasuhiro Fujisawa1, Manabu Fujimoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28069323     DOI： 10.1016/j.jdermsci.2016.12.019

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN： 0923-1811            Impact factor:   4.563


× No keyword cloud information.
  36 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

2.  Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.

Authors:  Kevin Tyan; Joanna Baginska; Martha Brainard; Anita Giobbie-Hurder; Mariano Severgnini; Michael Manos; Rizwan Haq; Elizabeth I Buchbinder; Patrick A Ott; F Stephen Hodi; Osama E Rahma
Journal:  Cancer Immunol Immunother       Date:  2021-01-22       Impact factor: 6.968

Review 3.  Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.

Authors:  Mitchell S von Itzstein; Shaheen Khan; David E Gerber
Journal:  Clin Chem       Date:  2020-06-01       Impact factor: 8.327

4.  Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.

Authors:  S D Saibil; L Bonilla; H Majeed; V Sotov; D Hogg; M A Chappell; M Cybulsky; M O Butler
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

Review 5.  Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.

Authors:  Caroline A Nebhan; Douglas B Johnson
Journal:  Expert Rev Anticancer Ther       Date:  2020-02-05       Impact factor: 4.512

6.  Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Authors:  Jonathan B Lamano; Jason Balquidera Lamano; Yuping D Li; Joseph D DiDomenico; Winward Choy; Dorina Veliceasa; Daniel E Oyon; Shayan Fakurnejad; Leonel Ampie; Kartik Kesavabhotla; Rajwant Kaur; Gurvinder Kaur; Dauren Biyashev; Dusten J Unruh; Craig M Horbinski; C David James; Andrew T Parsa; Orin Bloch
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

Review 7.  The intersection of COVID-19 and cancer: signaling pathways and treatment implications.

Authors:  Zhi Zong; Yujun Wei; Jiang Ren; Long Zhang; Fangfang Zhou
Journal:  Mol Cancer       Date:  2021-05-17       Impact factor: 27.401

Review 8.  Current status and future perspectives of immunotherapy in bladder cancer treatment.

Authors:  Zhangsong Wu; Jinjian Liu; Ruixiang Dai; Song Wu
Journal:  Sci China Life Sci       Date:  2020-08-26       Impact factor: 6.038

9.  Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.

Authors:  I-Ying Kuo; You-En Yang; Pei-Shan Yang; Yu-Jou Tsai; Hong-Tai Tzeng; Hung-Chi Cheng; Wan-Ting Kuo; Wu-Chou Su; Chih-Peng Chang; Yi-Ching Wang
Journal:  Theranostics       Date:  2021-05-12       Impact factor: 11.556

Review 10.  The dark side of immunotherapy.

Authors:  Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.